10X Genomics Inc (TXG) Financials

$65.60

$2.95 (4.71%)

As on 08-Sep-2026 16:26EDT

Market cap

$8,163 Mln

Revenue (TTM)

$617 Mln

P/E Ratio

--

P/B Ratio

10

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	616.91	642.82	610.79	618.73	516.41	490.49
Cost of Revenue	184.88	198.94	196.30	209.41	120.39	74.09
Gross Profit	432.03	443.88	414.48	409.31	396.02	416.40
Operating Expenses	520.41	554.77	609.04	674.64	563.97	469.31
Operating Profit (EBIT)	-88.38	-110.89	-194.56	-265.33	-167.94	-52.91
Other Income	--	--	--	--	6.45	-0.60
Profit before Tax	-74.89	-39.91	-177.70	-248.76	-161.97	-53.72
Provision for Tax	0.24	3.64	4.93	6.34	4.03	4.51
Profit after Tax (Net Income)	-75.13	-43.54	-182.63	-255.10	-166.00	-58.22
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-166.00	-58.22

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	825.55	796.33	710.13	741.04	805.74	817.57
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	86.01	91.59	90.87	96.94	92.28	90.90
Current Liabilities	118.51	153.45	117.63	127.16	130.96	110.36
Total Liabilities	1,148.58	1,041.37	918.64	965.14	1,028.98	1,018.83

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	355.40	356.91	334.25	369.12	393.95	271.24
Current Assets	674.67	684.45	584.39	596.02	635.04	747.59
Total Assets	1,148.58	1,041.37	918.64	965.14	1,028.98	1,018.83
Total Debt*	78.80	157.74	82.61	95.37	95.18	81.98
Net Current Assets	556.16	531.00	466.75	468.86	504.08	637.23

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	136.05	6.66	-15.20	-33.61	-21.37
Cash Flow from Investing Activities	--	-13.44	-32.63	133.49	-350.89	-106.73
Cash from Financing Activities	--	6.80	10.91	13.67	15.82	35.30
Net Cash Inflow / Outflow	--	--	--	--	-368.68	-92.81

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.59	-0.34	-1.50	-2.15	-1.45	-0.52
Cash EPS ($)	--	0.00	-1.14	-1.78	-1.16	-0.27
Adjusted Book Value ($)	--	6.27	5.84	6.25	7.02	7.31
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	1.07	0.05	-0.13	-0.29	-0.19
Free Cash Flow per Share ($)	--	1.02	-0.05	-0.55	-1.44	-1.10

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-4.99	-22.42	-29.37	-18.44	-6.84
ROE (%)	-9.26	-5.78	-25.17	-32.98	-20.45	-7.48
ROA (%)	-6.71	-4.44	-19.39	-25.59	-16.21	-5.98
EBIT Margin (%)	1.68	-6.21	-29.09	-40.20	-31.27	-10.77
Net Margin (%)	-12.18	-6.77	-29.90	-41.23	-31.75	-11.88
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-4.28	0.05	-0.01	0.20	0.05	0.64
EBIT Growth (%)	113.10	77.54	28.56	-54.02	-205.58	90.08
Net Profit Growth (%)	11.20	76.16	28.41	-53.67	-185.11	89.27
EPS Growth (%)	16.01	0.77	0.30	-0.49	-1.78	0.90
Book Value Growth (%)	2.26	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-47.60	-9.56	-26.01	-25.19	-286.28
Price / Book Value	9.97	2.60	2.46	8.95	5.19	20.39
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	148.50	436.68	-10.71	-30.92	-29.94	-657.15
Close Price ($)	38.34	16.31	14.36	55.96	36.44	148.96
High Price ($)	38.68	20.34	55.96	63.57	154.10	208.99
Low Price ($)	11.16	6.78	12.95	33.79	23.81	128.15
Market Cap ($ Cr)	8,162.74	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.20	0.12	0.13	0.12	0.10
Short term debt to equity ratio	0.01	0.01	0.01	0.02	0.01	0.01
Current Ratio	5.69	4.46	4.97	4.69	4.85	6.77
Quick Ratio	5.25	4.09	4.26	4.11	4.23	6.23
Interest Coverage	-24,962.33	--	-44,424.00	-7,537.27	-339.28	-61.03

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	8.21	12.83	14.39	18.56	20.18	17.38
Asset Turnover	0.55	0.66	0.65	0.62	0.50	0.50
Receivable days	--	48.40	60.61	64.65	67.00	50.81
Inventory Days	--	128.01	145.89	135.46	214.80	221.65
Payable days	--	23.54	26.65	32.56	59.09	54.38
Cash Conversion Cycle	--	152.87	179.84	167.56	222.72	218.09

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.